4th Inflammasome Therapeutics Summit 2022

Leading with practical insights from the best in the industry, the 4th Annual Inflammasome Therapeutics Summit is returning in person on November 29 – December 1 to Boston to equip you with the knowledge and connections to propel the next frontier of inflammasome therapeutics from pipeline to clinical and commercial reality.

Download the full event guide here for the official agenda.

Pick the brains of 140+ senior level drug developers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drug development.

Here’s a snapshot of the senior experts set to be attending:

Hao Wu, Asa & Patricia Springer Professor, Boston Children’s Hospital & Harvard Medical School
Alan Watt, Chief Scientific Officer, NodThera
Marc Pelletier, Senior Principal Scientist – Translational Immune Oncology, Novartis
Kate Fitzgerald, Professor & Vice Chair, Department of Medicine, Division of Innate Immunity, University of Massachusetts Chan Medical School
Giulia D’Urso, Senior Clinical Scientist, Hoffmann- La Roche
Stephen Glover, Co-Founder, Chairman & Chief Executive Officer, ZyVersa
Michael Crackower, Chief Scientific Officer, Ventus Therapeutics
Kevin Wilhelmsen, Associate Director of Immunology, BIOAGE Labs
Salvatore Alesci, Chief Scientific Officer, Invea Therapeutics
Hal Hoffman, Professor of Pediatrics & Medicine & Chief of the Division of Allergy, Immunology and Rheumatology in the Department of Pediatrics, UC San Diego/Rady Children’s Hospital